New Vaccine Against Tuberculosis:Current Developments and Future Challenges

被引：0
作者：
Jun Liu (Department of Molecular Genetics
机构：
来源：
Science Foundation in China | 2009年 / 17卷 / 02期
关键词：
Tuberculosis; BCG; Vaccine;
D O I：
10.16262/j.cnki.1005-0841.2009.02.004
中图分类号：
R52 [结核病];
学科分类号：
1002 ; 100201 ;
摘要：
Tuberculosis(TB) continues to be a global health threat.BCG was developed as an attenuated live vaccine for tuberculosis control nearly a century ago.Despite being the most widely used vaccine in human history,BCG is not an ideal vaccine and has two major limitations:its poor efficacy against adult pulmonary TB and its disconcerting safety in immunocompromised individuals.A safer and more effective TB vaccine is urgently needed.This review article discusses current strategies to develop the next generation of TB vaccines to replace BCG. While some progresses have been made in the past decade,significant challenges lie ahead.
引用
收藏
页码：50 / 56
页数：7
相关论文
共 14 条
  • [1] Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates
    Larsen, Michelle H.
    Biermann, Karolin
    Chen, Bing
    Hsu, Tsungda
    Sambandamurthy, Vasan K.
    Lackner, Andrew A.
    Aye, Pyone Pyone
    Didier, Peter
    Huang, Dan
    Shao, Linyun
    Wei, Huiyong
    Letvin, Norman L.
    Frothingham, Richard
    Haynes, Barton F.
    Chen, Zheng W.
    Jacobs, William R., Jr.
    [J]. VACCINE, 2009, 27 (34) : 4709 - 4717
  • [2] Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens;pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis[J] . Ronggai Sun,Yasir A.W. Skeiky,Angelo Izzo,Veerabadran Dheenadhayalan,Zakaria Imam,Erica Penn,Katherine Stagliano,Scott Haddock,Stefanie Mueller,John Fulkerson,Charles Scanga,Ajay Grover,Steven C. Derrick,Sheldon Morris,David M. Hone,Marcus A. Horwitz,Stefan H.E. Kaufmann,Jerald C. Sadof
  • [3] Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety
    Chen, Jeffrey M.
    Islam, Salim T.
    Ren, Huiping
    Liu, Jun
    [J]. VACCINE, 2007, 25 (48) : 8114 - 8122
  • [4] Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness[J] . B Bourdin Trunz,PEM Fine,C Dye.The Lancet . 2006 (9517)
  • [5] The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs
    Martin, C
    Williams, A
    Hernandez-Pando, R
    Cardona, PJ
    Gormley, E
    Bordat, Y
    Soto, CY
    Clark, SO
    Hatch, GJ
    Aguilar, D
    Ausina, V
    Gicquel, B
    [J]. VACCINE, 2006, 24 (17) : 3408 - 3419
  • [6] The ‘experimental stable’ of the BCG vaccine: safety, efficacy, proof, and standards, 1921–1933[J] . Christian Bonah.Studies in History and Philosophy of Biol ＆ Biomed Sci . 2005 (4)
  • [7] Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins[J] . Marcus A. Horwitz.Microbes and Infection . 2005 (5)
  • [8] Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur
    Brosch, R
    Gordon, SV
    Buchrieser, C
    Pym, AS
    Garnier, T
    Cole, ST
    [J]. YEAST, 2000, 17 (02) : 111 - 123
  • [9] Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree[J] . Tubercle and Lung Disease . 1999 (4)
  • [10] A historical and molecular phylogeny of BCG strains[J] . M.A Behr,P.M Small.Vaccine . 1999 (7)
12